Viking Therapeutics, Inc.

Form 3

April 28, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

 SINGLETON J MATTHEW

(Last)

(First)

(Middle)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

(Month/Day/Year)

04/28/2015

Statement

4. Relationship of Reporting

Person(s) to Issuer

X Director

Officer

5. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Form filed by More than One

Filed(Month/Day/Year)

C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE

50

(City)

(Instr. 4)

1. Title of Security

(Street)

(Check all applicable)

Viking Therapeutics, Inc. [VKTX]

10% Owner Other (give title below) (specify below)

SAN DIEGO, CAÂ 92037

(State)

Table I - Non-Derivative Securities Beneficially Owned

(Instr. 4)

2. Amount of Securities Beneficially Owned

Ownership

Form:

4. Nature of Indirect Beneficial

Reporting Person

Person

Ownership (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Zip)

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

4. 5. Ownership Conversion or Exercise Form of Price of Derivative

Derivative

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Security:

Edgar Filing: Viking Therapeutics, Inc. - Form 3

Date Expiration Title Exercisable Date

Amount or Security Number of Shares Direct (D) or Indirect (I) (Instr. 5)

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

SINGLETON J MATTHEW

C/O VIKING THERAPEUTICS, INC.

11119 NORTH TORREY PINES ROAD, SUITE 50 SAN DIEGO, CAÂ 92037

ÂX

Â

Â

Signatures

/s/ Brian Lian, Ph.D., as Attorney-in-Fact

04/28/2015

**Signature of Reporting Person

Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Â

Remarks:

No securities are beneficially owned Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2